Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy (scientific article published on 26 March 2018)

The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated

Q84203423

Two-dimensional-strain echocardiography in intensive care unit patients: A prospective, observational study

Q87413975

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

Q95784163

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

Q26771331

Cancer statistics, 2015

Q27860576

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

Q28328801

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Q30401812

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Q33428423

Expert consensus document on arterial stiffness: methodological issues and clinical applications

Q33999785

Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology,

Q34125322

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

Q34199968

A formula to estimate the approximate surface area if height and weight be known. 1916.

Q34437560

Recommendations for chamber quantification

Q34491436

Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma

Q35459791

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Q36065299

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Q36797893

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

Q36988282

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

Q37057941

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

Q37781587

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Q37835571

Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature

Q38042295

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.

Q38115568

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

Q38202358

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Q38364873

New pharmacotherapy options for multiple myeloma

Q38673764

Oxidative stress and proteasome inhibitors in multiple myeloma

Q38717135

Management of Carfilzomib-Associated Cardiac Adverse Events

Q38747358

'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors

Q40582501

How to image cardiac amyloidosis

Q41867190

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

Q43127820

Three-dimensional speckle strain echocardiography is more accurate and efficient than 2D strain in the evaluation of left ventricular function

Q43979374

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

Q44915315

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Q46119731

Reliability and feasibility of longitudinal AFI global and segmental strain compared with 2D left ventricular volumes and ejection fraction: intra- and inter-operator, test-retest, and inter-cycle reproducibility.

Q48690868

Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

Q48771344

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Q49060993

P433

issue

P304

page(s)

209-218

P577

publication date

2018-03-26

P1433

published in

High Blood Pressure & Cardiovascular Prevention

Q24031395

P1476

title

Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy

P478

volume

Reverse relations

cites work (P2860)

Q64945244	Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy.
Q92793814	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies
Q64883255	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.
Q96305532	The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity